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Abstract
Background: Fibroblast growth factor-23 (FGF-23), a novel regulator of mineral metabolism, is markedly elevated
in chronic kidney disease and has been associated with poor long-term outcomes. However, whether FGF-23 has
an analogous role in acute kidney injury is unknown. The goal of this study was to measure FGF-23 levels in
critically ill patients with acute kidney injury to determine whether FGF-23 levels were elevated, as in chronic
kidney disease.
Methods: Plasma FGF-23 and intact parathyroid hormone (PTH) levels were measured in 12 patients with acute
kidney injury and 8 control subjects.
Results: FGF-23 levels were significantly higher in acute kidney injury cases than in critically ill subjects without
acute kidney injury, with a median FGF-23 level of 1948 RU/mL (interquartile range (IQR), 437-4369) in cases
compared with 252 RU/mL (IQR, 65-533) in controls (p = 0.01). No correlations were observed between FGF-23 and
severity of acute kidney injury (defined by the Acute Kidney Injury Network criteria); among patients with acute
kidney injury, FGF-23 levels were higher in nonsurvivors than survivors (median levels of 4446 RU/mL (IQR, 3455-
5443) versus 544 RU/mL (IQR, 390-1948; p = 0.02). Severe hyperparathyroidism (defined as intact PTH >250 mg/dL)
was present in 3 of 12 (25%) of the acute kidney injury subjects versus none of the subjects without acute kidney
injury, although this result did not meet statistical significance.
Conclusions: We provide novel data that demonstrate that FGF-23 levels are elevated in acute kidney injury,
suggesting that FGF-23 dysregulation occurs in acute kidney injury as well as chronic kidney disease. Further
studies are needed to define the short- and long-term clinical effects of dysregulated mineral metabolism in acute
kidney injury patients.
Introduction
Acute kidney injury (AKI) is the most common reason
for inpatient nephrology consultation and is associated
with in-hospital mortality rates of 45-70% [1,2]. Until
recently, studies of AKI have focused on the epidemiol-
ogy and management of AKI during the index hospitali-
zation. However, AKI is now recognized as a disease with
long-term sequelae, including increased risk of death and
chronic kidney disease (CKD) progression [3-10]. The
mechanisms by which AKI is linked to adverse long-term
outcomes are poorly understood. Changes commonly
found in CKD patients–anemia, acid/base dysregulation,
altered mineral metabolism–likely occur in AKI patients,
and as in CKD patients, may be responsible for some of
these adverse long-term sequelae.
Dysregulated mineral metabolism, including derange-
ments in calcium and phosphate levels, is relatively well
characterized in CKD, and correction of hypocalcemia,
vitamin D deficiency, and hyperphosphatemia in CKD
patients is standard-of-care [11-13]. These derangements
are all associated with an increased risk of death and
cardiovascular outcomes in patients with CKD and
end-stage renal disease [14-22]. Interestingly, although
hypocalcemia and hyperphosphatemia are commonly
observed in patients with AKI, the literature on dysregu-
lated mineral metabolism in this patient population is
relatively limited. Some papers have concentrated on
rhabdomyolysis-induced AKI, where hyperphosphatemia
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is extreme due to tissue breakdown [23-30]. Several
studies included patients with AKI due to causes
other than rhabdomyolysis [23,30-35], but these were
published 30 or more years ago and did not measure
more novel regulators of mineral metabolism, such as
fibroblast growth factor-23 (FGF-23).
FGF-23 is a 26-kD protein that is a novel, key
regulator of phosphorus excretion and contributes to
abnormal bone metabolism in CKD [36]. FGF-23 has
been shown to be a strong, independent predictor of
death in ESRD and CKD [37-39]. To date, only one case
report has explored the impact of AKI on levels of FGF-
23 and that was in the setting of rhabdomyolysis [40].
We sought to determine the impact of AKI on FGF-23
and parathyroid hormone (PTH) levels in patients with
AKI due to causes other than rhabdomyolysis. If FGF-23
is elevated in this context, we hypothesized that FGF-23
might represent a novel treatment target or a novel
predictor for poor outcomes in patients with AKI.
Methods
Study design, patient selection, and clinical data
collection
AKI cases and non-AKI control subjects (controls) were
selected from two prospective observational cohort
studies conducted at a tertiary care university hospital.
Cases were identified from a prospective study of all
patients with AKIN Stage I AKI [41] admitted to the
adult intensive care unit of University of California San
Francisco Medical Center between June 2006 and
March 2009. Control subjects without AKI were
identified from a prospective study of all critically ill
Emergency Department patients eligible for admission
to the adult intensive care unit of University of Califor-
nia San Francisco Medical Center from October 2008 to
the present. The protocols were approved by the Institu-
tional Committee on Human Research.
Baseline creatinine was defined as the lowest
creatinine from the 365 days before admission until the
episode of AKI for AKI subjects. For control subjects,
baseline creatinine were the lowest creatinine from the
365 days before admission until hospital admission.
Potential subjects with a baseline creatinine of greater
than 1.1 mg/dL were excluded to eliminate subjects
with underlying CKD, which would impact FGF-23 and
PTH levels. Cause of AKI was determined by two
nephrologists (KDL, RH) based on chart review. Each
nephrologist independently reviewed the medical record
to determine the cause of AKI; there was 100%
agreement between the two reviewers.
Biomarker measurements
Plasma samples obtained from cases and controls were
immediately spun at 3000 rpm for 10 minutes and were
aliquoted and stored at -80°C until biomarker measure-
ments were made. For AKI cases, samples were obtained
at regular intervals during the first week that the patient
met criteria for AKI; measurements were made on the
sample from the time point closest to the peak serum
creatinine. For controls, measurements were made on
samples obtained immediately after admission. Intact
PTH measurements were made using Immulite 2000
Intact PTH assay (Siemens, Deerfield IL). FGF-23 mea-
surements were made using a C-terminal FGF-23 ELISA
(Immutopics, San Clemente, CA) according to the
manufacturer’s instructions. The reported calcium and
phosphorus measurements were made as part of routine
clinical care; the reported measurements are the closest
available relative to the time of biosample collection.
Statistical analyses
Baseline characteristics of cases and controls were first
compared. Categorical variables were expressed as pro-
portions, and compared using the c2 test. Continuous
variables were expressed as mean ± standard deviation
or median with interquartile range and were compared
using the t test or the Mann-Whitney rank-sum test,
where appropriate. Spearman rank correlation coeffi-
cients were used to correlate FGF-23 levels with serum
phosphorus, calcium, and PTH levels. Linear regression
analysis was used to examine the relationship between
FGF-23 levels and AKI status, after controlling for age
and severity of illness, as measured by Acute Physiology
And Chronic Health Evaluation (APACHE) II score
[42]; because FGF-23 levels were not normally distribu-
ted, levels were natural log transformed for this analysis.
Data analysis was conducted by using Stata 10.1 (Stata-
Corp, College Station, TX). Two-tailed p values < 0.05
were considered significant.
Results
The baseline demographics and clinical characteristics of
the 20 subjects in this study are summarized in Table 1.
We studied 12 cases who developed at least Stage I AKI
and 8 control subjects who did not. Cases and controls
were similar with regard to sex and race. On average,
cases were younger than controls (57 ± 12 years versus
70 ± 17 years, p = 0.05) and had lower APACHE II
scores (27 ± 11 versus 17 ± 8, p = 0.04). There was no
statistically significant difference for in-hospital mortal-
ity rates between the two groups.
Subjects with AKI had a baseline serum creatinine of
67 ± 15 μmol/L with a peak inpatient serum creatinine
of 217 ± 86 μmol/L compared with a baseline serum
creatinine of 69 ± 20 μmol/L and a peak serum creati-
nine of 81 ± 17 in non-AKI subjects (p < 0.001 for peak
levels). As noted earlier, we excluded potential study
subjects with a baseline creatinine greater than 97
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μmol/L to avoid patients with underlying CKD. No
patient had AKI attributable to rhabdomyolysis. Eight
patients had acute tubular necrosis, two patients had
AKI after orthotopic liver transplantation, one had car-
diorenal syndrome, and one had multifactorial AKI.
Two patients had Stage I AKI by the AKIN criteria [41],
five patients had Stage II AKI, and five patients had
Stage III AKI. Four of 12 (33%) of the AKI subjects
were treated with dialysis.
Subjects with and without AKI had mean ionized cal-
cium levels of 1.19 ± 0.1 mmol/L and 1.15 ± 0.08,
respectively (p = 0.41). Serum phosphorus levels were
significantly higher in AKI subjects compared with
controls (4.5 ± 1 mmol/L versus 3.3 ± 1.1 mmol/L,
p = 0.02). The median intact PTH level was 63 mg/dL
(25-75% interquartile range (IQR), 38-213) in AKI subjects
and 70 mg/dL (25-75% IQR, 58-126) in controls (Figure
1A, p = 0.73). When severe hyperparathyroidism was
defined as an intact PTH >250 mg/dL, a level that has
been associated with increased cardiovascular disease risk
in prior studies [43], none of the control subjects had a
severe hyperparathyroidism but 3 of 12 (25%) of the AKI
subjects did (although this result did not meet conven-
tional levels of statistical significance, p = 0.24).
FGF-23 levels were significantly higher in critically ill
AKI cases compared with critically ill non-AKI subjects,
with a median FGF-23 level of 1948 RU/mL (IQR, 437-
4369) in AKI cases compared with 252 RU/mL (IQR,
65-533) in critically ill controls (p = 0.01; Figure 1B).
After adjusting for age and APACHE II as potential
confounders, AKI remained a significant predictor of
log-transformed FGF-23 levels (Table 2). Among
patients with AKI, FGF-23 levels were higher in nonsur-
vivors (n = 4) compared with survivors (n = 8), with
respective median levels of 4446 RU/mL (IQR, 3455-
5443) versus 544 RU/mL (IQR, 390-1948; p = 0.02).
Although serum phosphorus and FGF-23 levels were
both elevated in AKI subjects, no correlation was
observed between the two variables, as shown in Figure 2
(r = 0.08, p = 0.74). There was a correlation between
PTH and FGF-23 levels (r = 0.55, p = 0.02); when this
analysis was restricted to patients with AKI, this correla-
tion only had borderline statistical significance (r = 0.58,
p = 0.05), likely due to the small size of the cohort.
Discussion
In this cross-sectional case series, we report for the first
time that critically ill patients with AKI due to causes
other than rhabdomyolysis have elevated FGF-23 levels
compared with critically ill controls. Among patients
with AKI, elevated FGF-23 levels were associated with
an increased risk of death. As expected, AKI patients
had, on average, higher concentrations of serum
phosphorous compared with patients without AKI. In
addition, a larger proportion of AKI patients had signifi-
cant hyperparathyroidism compared with controls,
although this result did not meet statistical significance.
These results suggest that dysregulated mineral metabo-
lism is common in AKI, analogous to CKD.
Interestingly, no correlation was observed between
phosphorous and FGF-23 levels in this study. Few reports
have analyzed this relationship in AKI patients, although
in ESRD a patient’s degree of elevation in FGF-23 is often
correlated with severity of hyperphosphatemia [38,44,45].
In CKD, elevated FGF-23 levels are thought to be due to
increased secretion by bone cells, rather than due to
decreased renal clearance [46,47]. Comparison of levels
of intact versus degraded FGF-23 in patients on mainte-
nance hemodialysis suggest that there is no increase in
FGF-23 degradation products in these subjects and that
decreased clearance of FGF-23 is therefore not the
mechanism for increased FGF-23 levels [48]. Therefore,
as in CKD, elevated FGF-23 levels in AKI are likely not
due to decreased clearance of FGF-23 and highlight the
Table 1 Baseline characteristics of patients with and without acute kidney injury
No acute kidney injury Acute kidney injury p value
Number 8 12
Age (yr)* 70 ± 17 57 ± 12 0.05
Male n (%) 2(25%) 6(50%) 0.37
Caucasian n (%) 4(50%) 10(83%) 0.16
APACHE II* 17 ± 8 27 ± 11 0.04
Death n (%) 3(38%) 4(33%) 1.00
Baseline Cr (μmol/L)* 69 ± 20 67 ± 15 0.83
Peak Cr (mg/dL)* 81 ± 17 217 ± 86 <0.001
Dialysis n (%) 0(0%) 4(33%) 0.11
Ionized calcium (mmol/L)* 1.15 ± 0.08 1.19 ± 0.1 0.41
Phosphorous (mmol/L)* 3.3 ± 1.1 4.5 ± 1 0.02
*Mean ± SD
To convert Cr in μmol/L to mg/dL, divide by 88.4
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Figure 1 PTH and FGF-23 levels in non-AKI and AKI subjects. A There was no overall difference in PTH levels between AKI and non-AKI
subjects (p = 0.73). B FGF-23 levels were significant higher in patients with AKI compared with non-AKI subjects (p = 0.01).
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important paracrine role of the kidney, even in an acute
illness (e.g., AKI).
Elevation of FGF-23 during AKI may have several
implications. In ESRD patients undergoing hemodialysis,
high FGF-23 concentrations are associated with early
mortality, with an increased risk as high as 600%
[37,38]. Our study demonstrated an association between
FGF-23 levels and death in subjects with AKI, although
relatively small. If the association between elevated FGF-
23 levels and death is confirmed in a larger study of
patients with AKI, prevention or treatment of such pro-
cesses could become a priority in AKI management.
Treatment with phosphate binders and calcimimetics
(Cinacalcet) has been shown to lower FGF-23 levels
[49-51]. Treatments that are tailored more toward AKI-
induced mineral dysregulation could be developed as
further information is gathered about the exact role of
FGF-23 in AKI. At present, there are no evidence-based
guidelines about target goals for maintaining serum
phosphorus levels. Treatments that improve the long-
term outcomes of patients with AKI are needed, and
dysregulated mineral metabolism, including FGF-23
levels, may represent a therapeutic target in AKI that is
highly amenable to intervention.
There are several limitations in this study, including
small sample size and relatively short follow-up time.
Because FGF-23 levels were not measured repeatedly,
duration of FGF-23 elevation also was unclear. Never-
theless, this is the first study to report an association
between FGF-23 and non-rhabdomyolysis-related AKI,
and that among patients with AKI, higher FGF-23
levels are associated with an increased risk of death.
Larger and long-term studies should be conducted to
clarify the impact of FGF-23 elevation among AKI
patients.
Conclusions
Dysregulated mineral metabolism is a poorly understood
aspect of acute kidney injury. We demonstrated for the
first time that FGF-23, a critical regulator of mineral
metabolism in chronic kidney disease, is upregulated
during acute kidney injury from causes other than
Table 2 Association of log-transformed FGF-23 levels
with AKI (multivariable linear regression)
Predictor Coefficient 95% CI p value
AKI 1.81 0.37-3.25 0.02
Age* 0.29 -0.15-0.73 0.18
APACHE II score 0.05 -0.02-0.11 0.14
*Per 10-year increase
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Figure 2 Correlation of serum phosphorus (PO4) and FGF-23 levels in patients with and without acute kidney injury. No correlation was
observed between PO4 and FGF-23 levels (r = 0.08, p = 0.74).
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rhabdomyolysis. Furthermore, high FGF-23 levels are
associated with mortality in patients with AKI.
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